简介：

简介：客观：在食管的恶意的阻塞上学习内视镜的治疗的效果。方法：先进食道的癌症病人的64个盒子有食管的阻塞，7个盒子不能被操作，57个盒子复发了在操作以后的损害和放射治疗。阻塞都与食道的扩张器被扩大，然后用elemene乳剂注射和stent的本地化疗，或本地管理被对待被放在食道的腔。结果：阻塞与膨胀被减轻仅仅大约一个星期，而是阻塞，用用另外的治疗在膨胀以后减轻了超过三个月。在膨胀以后，然而，癌的PR在本地化疗组是大约80%CR是大约8%，PR在elemene的组是大约92%乳剂注射。结论：内视镜的治疗是为先进食道的癌症的一个有效辩解的方法。

简介：Baseduponstudiesfromrandomizedclinicaltrials,theextended(D2)lymphnodedissectionisnowrecommendedasastandardprocedureforlocaladvancedgastriccancerworldwide.However,therationalextentlymphadenectomyforlocaladvancedgastriccancerhasremainedatopicofdebateinthepastdecades.Duetothelimitationoflowmetastaticrateinpara-aorticnodes(PAN)inJCOG9501,theclinicalbenefitofD2+para-aorticnodaldissection(PAND)forpatientswithstageT4and/orstageN3disease,whichisverycommoninChinaandothercountriesexceptJapanandKorea,cannotbedetermined.Furthermore,theroleofsplenectomyforcompleteresectionofNo.10andNo.11nodeshasbeencontroversial,andhowever,thefinalresultsfromtherandomizedtrialofJCOG0110haveyettobecompleted.GastriccancerwiththeNo.14andNo.13lymphnodemetastasisisdefinedasM1stageinthecurrentversionoftheJapaneseclassification.WeproposethatD2+No.14vand+No.13lymphadenectomymaybeanoptioninapotentiallycurativegastrectomyfortumorswithapparentmetastasistotheNo.6nodesorinfiltratetoduodenum.Theexaminedlymphnodeandextranodalmetastasisaresignificantlyassociatedwiththesurvivalofgastriccancerpatients.

简介：包括肠的组织变形(IM)和发育异常(Dys)评估在前列腺干细胞抗原(PSCA)和先进癌症前期的胃的损害的风险的基因多型性之间的关系的目的，基于人口的研究在Linqu被进行县，在中国的胃的癌症(GC)的一个高风险的区域。包括表面的胃炎(SG)的胃的损害的流行，长期的衰退胃炎(CAG)，IM和Dys被组织病理学说的检查决定的方法。遗传型被聚合酶链反应限制决定碎片长度多型性(PCR-RFLP)技术。IM和Dys的风险上的PSCA基因变体的效果被无条件的逻辑回归计算。结果Multivariate分析表明带PSCArs2294008CT/TT遗传型的题目与IM的增加的风险被联系(OR=1.38，95%CI=1.111.71)并且Dys(OR=1.75，95%CI=1.362.26)，特别为有H.pylori感染的题目(IM：OR=1.34，95%CI=1.051.71；Dys：OR=1.82，95%CI=1.372.42)。而且，H。pylori感染和PSCArs2294008CT/TT遗传型被观察联合提高IM的风险(OR=3.32，95%CI=2.334.71)并且Dys(OR=4.58，95%CI=2.997.04)。这研究建议了那PSCArs2294008的结论可能在GC的高风险人口之中影响IM或Dys的风险。

简介：

简介：Objective:Toassessthesafetyandclinicalantiangiogeniceffectofrecombinantadenovirus-p53(rAd-p53)combinedwithhyperthermiaplusornotplusradiotherapyinadvancedcancer.Methods:ExpressionofVascularepithelialgrowthfactor(VEGF)afterintratumoralinjectionofrAd-p53wasassayedbyimmunohistochemistry(IHC)imaging.Forty-fourpatientswithadvancedcancerwereenrolledintothisclinicalstudy.ThepatientswereintratumorallyinjectedwithrAd-p53(Gendicine)atadoseof1×1012vponceaweek,withatotalof4-54(mean7.7)times.Totalof4-29(mean8.5)timesofhyperthermiawasgiventothepatients.Amongthe44patients,30patientswereconcurrentlyaddedwithradiotherapyofatotaldose30-76Gy/15-38f/3-8w(mean58Gy).Results:BeforeandafterintratumoralinjectionofrAd-p53,theVEGFIHCpositivecellscoreswere2.80and1.50,respectively(P=0.031).ThetreatmentofrAd-p53combinedwithhyperthermiaplusornotplusradiotherapyinadvancedcancerachievedCRrateof13.60%(6/44),andPRrateof29.6%(13/44),andthustheeffectiveratewas43.2%.Inadditionto6patientswithCR,19patients(19/38,50.0%)hadlowdensityarea(LDA)ofmorethan50%areaonCTimagewithintumorindicatingtumortissuenecrosis.Conclusions:OurdataindicatethatrAd-p53inhibitsVEGFexpressionandangiogenesis,andpromotestumornecrosisandshrinkageinducedbyhyperthermiaplusornotplusradiotherapyinadvancedcancer.

简介：Objective:Previousworkindicatedthataneuploidyofchromosome8incirculatingtumorcells(CTCs)correlatedwiththerapeuticefficacyforadvancedgastriccancer(AGC)patients.Inthisfollow-upstudyperformedonthesamepopulationofAGCpatients,weinvestigatedwhetherandhowaneuploidyofchromosome8inCTCscorrelateswithpatients'clinicalprognosis.Methods:Theprospectivestudywasperformedon31patientswithnewlydiagnosedAGC.Previouslyestablishedintegratedsubtractionenrichment(SE)andimmunostaining-fluorescenceinsituhybridization(iFISH)platformwasappliedtoidentify,enumerateandcharacterizeCTCs.QuantificationofCTCsandanalysisoftheiraneuploidyofchromosome8wereperformedonpatientsbeforeandaftertherapy.Results:CTCsweremeasuredin93.5%ofAGCpatients,andtwoCTCsubtypeswithdiversethresholdvalueswereidentified,multiploidCTCswiththethresholdof≥2per7.5mLandmultiploidplustriploidCTCswiththethresholdof≥4,whichwerefoundtosignificantlycorrelatewithpoorprogression-freesurvival(PFS)andoverallsurvival(OS).Inparticular,patientswith≥10%increasedmultiploidCTCsafteraninitial6weeksoftherapyhadpoorPFSandOS,whereasimprovedPFSandOSwereobservedonthosewhohad≥10%decreasedmultiploidCTCs.Afteradjustingforclinicallysignificantfactors,≥10%increasedpost-therapymultiploidCTCswastheonlyindependentpredictorofPFSandOS.Conclusions:AneuploidyofCTCscorrelateswithprognosisofAGCpatients.QuantitativecomparisonmonitoringmultiploidCTCsbeforeandaftertherapymayhelppredictimprovedorinferiorprognosisandchemoresistance.

简介：Objective:ResponseEvaluationCriteriainSolidTumors(RECIST)guidelineversion1.0(RECIST1.0)wasproposedasanewguidelineforevaluatingtumorresponseandhasbeenwidelyacceptedasastandardizedmeasure.WithanumberofissuesbeingraisedonRECIST1.0,however,arevisedRECISTguidelineversion1.1(RECIST1.1)wasproposedbytheRECISTWorkingGroupin2009.ThisstudywasconductedtocompareCTtumorresponsebasedonRECIST1.1vs.RECIST1.0inpatientswithadvancedgastriccancer(AGC).Methods:Wereviewed61AGCpatientswithmeasurablediseasesbyRECIST1.0whowereenrolledinotherclinicaltrialsbetween2008and2010.Thesepatientswereretrospectivelyre-analyzedtodeterminetheconcordancebetweenthetworesponsecriteriausingtheκstatistic.Results:ThenumberandsumoftumordiametersofthetargetlesionsbyRECIST1.1weresignificantlylowerthanthosebyRECIST1.0(P<0.0001).However,therewasexcellentagreementintumorresponsebetweenRECIST1.1andRECIST1.0(κ=0.844).Theoverallresponserates(ORRs)accordingtoRECIST1.0andRECIST1.1were32.7%(20/61)and34.5%(20/58),respectively.Onepatientwithpartialresponse(PR)basedonRECIST1.0wasreclassifiedasstabledisease(SD)byRECIST1.1.OftwopatientswithSDbyRECIST1.0,onewasdowngradedtoprogressivediseaseandtheotherwasupgradedtoPRbyRECIST1.1.Conclusions:RECIST1.1providedalmostperfectagreementwithRECIST1.0intheCTassessmentoftumorresponseofAGC.

简介：Lungcancerrepresentstheleadingcauseofcancerdeathsinhuman.Non-smallcelllungcancer(NSCLC)accountsforabout75%--85%ofalllungcancersandcanbesurgicallyresectedinonly30%--40%ofpatientswithlimiteddisease.[1’21Theremainingpatients,withlocallyadvancedormetasta...

简介：Objective:Patientsundergoingtotalgastrectomyforcancerareatriskofmalnourishment.Theaimofthisselfcontrolledstudywastoexaminetheeffectofjejunostomytubefeeding(JTF)andotherfactorsonpostoperativeweightandtheincidenceofjejunostomy-relatedcomplicationsinpatientsundergoingtotalgastrectomyforcancer.Methods:Allconsecutivepatientswhounderwenttotalgastrectomyforgastriccancerwithjejunostomyplacementwereincludedfromaprospectivesingle-centerdatabase(2003–2014).Jejunostomy-relatedcomplicationsandpostoperativeweightchangeswereevaluatedupto12monthsaftersurgery.Multivariablelinearregressionanalysiswasperformedtoidentifyfactorsassociatedwithweightloss12monthsaftergastrectomy.Results:Of113patientsoperatedinthestudyperiod,65receivedJTFaftertotalgastrectomyforamediandurationof18d[interquartilerange(IQR),10–55d].Jejunostomy-relatedcomplicationsoccurredin11(17%)patients,includingskinleakage(n=3)andperitonealleakage(n=2),luxation(n=3),occlusion(n=2),infection(n=1)andtorsion(n=1).In2(3%)patients,areoperationwasneededduetojejunostomy-relatedcomplications.Themeanpreoperativeweightofpatientswas71.8kg(100%),andremainedstableduringJTF(73.9kg,103%,P=0.331).AfterJTFwasstopped,themeanweightofpatientsdecreasedto64.9kg(90%)at12monthsaftersurgery(P<0.001).Ahighpreoperativebodymassindex(BMI)(≥25kg/m~2)wasassociatedwithhighpostoperativeweightlosscomparedtopatientswithalowBMI(<25kg/m~2)(16.3%vs.8.6%,P=0.016).Conclusions:JTFcanpreventweightlossintheearlypostoperativephase.However,thisisattheprizeofpossiblecomplications.Asweightlossinthelongtermisnotprevented,routineJTFshouldbere-evaluatedandbalancedagainsttheselecteduseinpreoperativelymalnourishedpatients.SpecialattentionshouldbepaidtopatientswithahighpreoperativeBMI,whoareatriskofmorepostoperativeweightloss.

简介：比较在主要debulking外科(PDS)和neoadjuvant化疗之间的幸存和perioperative病态的目的在与先进上皮的卵巢的癌症(EOC)对待病人由间隔debulking外科(NAC/IDS)列在后面。我们回顾地与阶段IIIC或IVEOC考察了67个病人的方法从2006年1月在北京大学癌症医院对待到2009年6月。在那里，37和30个病人分别地经历了PDS和NAC/标志。结果在全面幸存(OS)或没有前进的幸存(PFS)的差别都没在NAC/IDS组和PDS组之间被观察(OS：41.2对39.1个月，P=0.23；PFS：27.1对24.3个月，P=0.37)。最佳的debulking率在NAC/IDS组是60%，它在PDS组(32.4%)(P=0.024)比那显著地高。NAC/IDS组显著地有比PDS的肠的功能的估计的血损失和输送，更低的nasogastricintubation率，和更早的移动和恢复组织的更少的intraoperative(P<0.05)。结论NAC/IDS不比PDS侵略，并且关于最佳的cytoreduction率，intraoperative血损失，和手术后的恢复提供优点，没有显著地损害与在对待有阶段IIIC或IVEOC的病人的PDS相比的幸存。因此，NAC/IDS可以是为EOC病人的一种珍贵治疗选择。

简介：客观试验性的证据建议胸的overexpression癌症特定的肿瘤suppressor蛋白质1(BRCA1)基因提高敏感到docetaxel和抵抗到cisplatin和ribonucleotidereductaseM1(RRM1)基因overexpression提高抵抗到gemcitabine。为了进一步检验BRCA1和RRM1mRNA的效果，在先进非小的房间肺癌症(NSCLC)在结果上铺平，我们执行了测试了那设定的治疗将授与的假设的这非使随机化的阶段II临床的审判在noncustomized上的改进结果治疗。

简介：

简介：Objective:Theaimofthisstudywastoestablishtheriskscoringsystemtowardstheadvancedcolorectalneoplasm(CN)riskintheaverage-riskpopulationsinthesouthernJiangsuProvince,andtoevaluatethescreeningefficacy.Methods:Totally905casesoftheaverage-riskpopulationswhoreceivedthecolonoscopywereselectedastheobjective.Themultivariatelogisticregressionanalysismethodwasusedtoestablishthescoringsystemtowardstheoccurrenceriskoftheadvancedtumor,anditsscreeningefficacywasevaluatedthroughthepredictionconsistency,distinguishingabilityandscreeningaccuracy.Results:Thescoringsystemconsistedoffivevariables,namelyage,gender,coronaryheartdisease,eggintakeandstoolfrequency.Theresultsrevealedthatithadgoodpredictionconsistency(P=0.205)anddistinguishingability[theareaunderthereceiveroperatingcharacteristic(ROC)curvewas0.75,with95%confidenceinterval(95%CI)of0.69-0.82].Thus,2.5pointswassetasthescreeningcutoffvalue,anditssensitivity,specificity,accuracy,positivepredictivevalue,negativepredictivevalue,positivelikelihoodratioandnegativelikelihoodratiowere93.8%,47.6%,50.1%,9.1%,99.3%,1.79and0.13,respectively.Conclusions:Theestablishedscoringsystemhadgoodscreeningefficacy,andcanbeusedasthescreeningtoolapplyingtotheCNscreeningwithintheaverage-riskpopulationsinthesouthernJiangsuProvince.

简介：Purpose:Anumberofdifferentclinicalcharacteristicshavebeenreportedtosinglycorrelatewiththerapeuticactivityofepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitors(TKIs)inadvancednon-small-celllungcancer(NSCLC).Thisstudyaimedtoidentifypredictivefactorsassociatedwithprognosticbenefitsofgefitinib.Patientsandmethods:EGFRgenetypingin33advancedNSCLCpatientsreceivedgefitinib(250mg/day)wereanalyzedwithmutant-enrichedPCRassay.Gefitinibresponsewasevaluatedwithpotentialpredictivefactorsretrospectively.Results:Theoverallobjectiveresponserate(ORR)andmedianprogression-freesurvival(PFS)inthe33patientstreatedbygefitinibwere45.5%and3.0(2.0-4.0)months.TheORRandmedianPFSinEGFRgenemutationpatientsweresignificantlyhigher/longerthanthoseinEGFRgenewild-typepatients(P<0.01).Similarly,theORRandmedianPFSinnon-smokerpatientsweresignificantlyhigher/longerthanthoseinsmokerpatients(P<0.05,P<0.01,respectively).However,nodifferenceforORRandmedianPFSoccurredbetweenmaleandfemalepatients.LogisticmultivariateanalysisshowedthatonlyEGFRmutatedgenewassignificantlyassociatedwiththeORR(P<0.01).BothEGFRmutatedgeneandnon-smokerwerethemajorfactorsthatcontributedtoPFS(P<0.05).Conclusions:EGFRmutatedgeneandnon-smokerstatusarepotentialpredictorsforgefitinibresponseinNSCLCpatients.

简介：Objective:Theaimofthisprospective,single-armphaseIItrialwastoconfirmthesafetyandefficacyofneoadjuvantchemotherapy(NAC)usingoxaliplatinpluscapecitabine(CapOX)forpatientswithoperablelocallyadvancedcoloncancer(CC).Methods:Patientswithcomputedtomography-definedT4orlymphnode-positiveCCswereenrolled.Afterradiologicalstaging,patientsweretreatedwithatleast2cyclesofNACconsistingof130mg/m2oxaliplatinond1,plus1,000mg/m2capecitabinetwicedailyfor14devery3weeks,followedbysurgery,andthenwiththerestcyclesofadjuvantchemotherapy.Radiologicalresponsewasevaluatedafter2cyclesofNAC.Tumorresponse,treatmenttoxicity,andsurgicalcomplicationswererecorded.Thepathologicalresponsetotherapywasevaluatedaccordingtothetumorregressiongrade(TRG)score.Theprimaryendpointwaspathologictumorresponse.ThistrialisregisteredinClinicalTrials.gov(No:NCT02415829).Results:Forty-sevenpatientswereenrolledinthestudy.Forty-twopatientscompletedtheplannedtreatments.Thetotalradiologicalresponseratewas68%(32/47),includingcompleteandpartialresponseratesof2%(1/47)and66%(31/47),respectively.Stablediseasewasobservedin32%(15/47)andprogressivediseasewasobservedinnone.Completepathologicresponse,majorregression,andatleastmoderateregressionwereachievedin1(2%),2(4%),and29(62%)patients,respectively.Fourpatientsdevelopedgrade3treatmenttoxicities.Onepatientwithwoundinfectionoccurredafteroperation(1/47,2%).Therewasnotreatment-relateddeath.Conclusions:OurresultssuggestthatNACwithCapOXisaneffectiveandsafetreatmentoptionforpatientswithlocallyadvancedCCs.

简介：在病人作为首要或第二线的治疗评估paclitaxel，cisplatin和5-FU(PCF)的联合政体的功效和毒性与的目的进展胃并且在中国的esophagogastric连接(EGJ)腺癌。病人与paclitaxel被对待的方法d1上的150mg/m2；fractionatedcisplatin15mg/m2和连续注入5-FU600mg/(m2朠楬污映扩楲汬牡????????????М

简介：Molecularsubtypingofbreastcancermayprovideadditionalprognosticinformationregardingpatientoutcome.Theepidermalgrowthfactorreceptor(HER2)overexpressingbreastcancersaredesignatedasHER2-postive(HER2+)breastcancerandcarryaparticularlyunfavorableprognosis.WepresenttwocasesofHER2-postivemetastaticbreastcancer(MBC)whoarefoundtobeachallengetotreat,especiallyduetotheoccurrenceofbrainmetastasis.Trastuzumab-basedtherapyimprovesclinicaloutcomes,evenifthepatienthasundergonemulti-linetreatment.ThesecasereportsalsoemphasizetheimportanceofretestingHER2statusbecauseitcanbediscordanceinreceptorstatusbetweenprimaryandrecurrentbreastcancer.

简介：Purpose:Wntpathwayscontrolkeybiologicalprocessesthatpotentiallyimpactontumorprogressionandpatientsurvival.Thepresentstudyanalyzedthepolymorphismoflipoprotein-relatedreceptor5(LRP5)(genewithkeyfunctionsinWntsignaling)anditsimpactontheresponsetochemotherapyandsurvivalofpatientswithadvancedgastriccancer(AGC).Methods:Atotalof107consecutivepatientswithAGCtreatedwithfirst-linechemotherapyofEOFregimenwereenrolledinthepresentretrospectivestudy.Theassociationbetweensinglenucleotidepolymorphism(SNP)ofrs3736228inLRP5andtheclinicaloutcomesofthepatientswasstudied.Results:TheCCgenotypeofrs3736228wassignificantlycorrelatedwithahigherdiseasecontrolratewhencomparedtotheCTandTTgenotypes(89.3%and61.8%,respectively,P<0.001).Aunivariatesurvivalanalysisalsoshowedthattheprogressionfreesurvival(PFS)andoverallsurvival(OS)forthepatientswiththeTCandTTgenotypesofrs3736228wereworsethanforthepatientswiththeCCgenotype(PFS:3.3and6.7months,respectively,HR=0.454,P<0.001;OS:8.1monthsand18.8months,respectively,HR=3.056,P<0.001).AmultivariateCoxmodelincorporatesrs3736228andclinicalfeatures,alsoidentifiedrs3736228wassignificantlyassociatedwiththePFSandOS.Conclusions:OurresultsfirstlyhighlighttheimportanceofLRP5geneofWntpathwayinthetreatmentofAGCandidentifypolymorphismofrs3736228asindependentpredictorofdiseasecontrolrate,PFSandOSinAGCpatientstreatedwithfirst-linechemotherapyofEOFregimenintheChineseHanpopulation.

简介：Objective:Non-smallcelllungcancer(NSCLC)patientswithepidermalgrowthfactorreceptor(EGFR)-activatingmutationshavehigherresponserateandmoreprolongedsurvivalfollowingtreatmentwithsingle-agentEGFRtyrosinekinaseinhibitor(EGFR-TKI)comparedwithpatientswithwild-typeEGFR.However,allpatientstreatedwithreversibleinhibitorsdevelopacquiredresistanceovertime.Themechanismsofresistancearecomplicated.ThelackofestablishedtherapeuticoptionsforpatientsafterafailedEGFR-TKItreatmentposesagreatchallengetophysiciansinmanagingthisgroupoflungcancerpatients.ThisstudyevaluatestheinfluenceofEGFR-TKIretreatmentfollowingchemotherapyafterfailureofinitialEGFR-TKIwithinatleast6monthsonNSCLCpatients.Methods:Thedataof27patientswhoexperiencedtreatmentfailurefromtheirinitialuseofEGFR-TKIwithinatleast6monthswereanalyzed.Afterchemotherapy,thepatientswereretreatedwithEGFR-TKI(gefitinib250mgqdorerlotinib150mgqd),andthetumorprogressionwasobserved.Thepatientswereassessedforadverseeventsandresponsetotherapy.TargetedtumorlesionswereassessedwithCTscan.Results:Ofthe27patientswhoreceivedEGFR-TKIretreatment,1(3.7%)patientwasobservedincompleteresponse(CR),8(29.6%)patientsinpartialresponse(PR),14(51.9%)patientsinstabledisease(SD),and4(14.8%)patientsinprogressivedisease(PD).Thediseasecontrolrate(DCR)was85.2%(95%CI:62%-94%).Themedianprogression-freesurvival(mPFS)was6months(95%CI:1-29).Ofthe13patientswhoreceivedthesameEGFR-TKI,1patientinCR,3patientsinPR,8patientsinSD,and2patientsinPDwereobserved.TheDCRwas84.6%,andthemPFSwas5months.Ofthe14patientswhoreceivedanotherEGFR-TKI,nopatientinCR,6patientsinPR,6patientsinSD,and2patientsinPDwereobserved.TheDCRwas85.7%,andthemPFSwas9.5months.SignificantdifferencewasfoundbetweenthetwogroupsinPFSbutnotinresponserateorDCR.Conclusion:RetreatmentofEGFR-TKIscanbeconsideredano